Even though the effects of therapy in this patient are not fully clarified, our results suggest that combination therapy with Trastuzumab, Pertuzumab and Paclitaxel following the schedule and posology presented in this study may be a good treatment for recurrent HER2-positive breast cancer with visceral crisis and severe liver dysfunction. Here, ERBB2 is linked to breast carcinoma.